This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Genta Takes Another Stab


Onward. Thomas L. writes, "Hi Adam, I know you don't have time to comment on every email you get, but I was wondering if you could comment on Osiris Therapeutics (OSIR - Get Report) and their diabetes cure."

Thomas sent along a link to a story in a U.K. publication about research with Osiris' stem-cell drug Prochymal in patients with Type 1 diabetes.

My comment: Don't believe the hype. The dismal failure of Prochymal in two studies of patients with graft-vs.-host disease, coupled with the previous setbacks in Crohn's disease and knee cartilage repair, are more than enough to send Prochymal to the drug development graveyard.

Osiris is a zombie stock -- dead but acting as if it's still alive.


That last line also answers Zach P.'s email. He asked, "Any thoughts on why Osiris isn't sitting closer to cash levels given the placebo-like results for Prochymal."

Osiris equals the living dead.


Rick K. emails with a question about this week's obesity drug data from Vivus (VVUS - Get Report).

"Qnexa is simply phentermine and topamax, both available today. So why wait for or use Qnexa?"

Rick's question is a good one and highlights one of the commercial concerns raised about Qnexa. Generic phentermine is widely prescribed as a weight-loss drug today, so what stops doctors from adding a prescription for generic topirimate, instead of reaching for branded Qnexa?

Vivus responds by stating that the dosages of phentermine and topiramate used in Qnexa are not available generically. The patented formulation of the two drugs into Qnexa -- delayed-release topirimate and immediate-release phentermine -- also plays a role in the drug's efficacy, according to Vivus.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AGEN $7.62 -2.60%
ARNA $3.98 -0.62%
OPXA $0.61 17.56%
OSIR $18.69 0.00%
VVUS $2.50 -1.20%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs